Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians

Kidney International

Volumn 70, Issue 10, 2006, Pages 1840-1846

  Pavkov, M E ^a   Knowler, W C ^a   Bennett, P H ^a   Looker, H C ^a   Krakoff, J ^a   Nelson, R G ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

ACE inhibitors; Diabetes mellitus; End stage renal disease; Proteinuria

Indexed keywords

CREATININE; PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE REGULATION; CONFIDENCE INTERVAL; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE DURATION; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INDIAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SEX DIFFERENCE;

ADULT; ARIZONA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; ISLETS OF LANGERHANS; KIDNEY FAILURE, CHRONIC; LINKAGE (GENETICS); MALE; MIDDLE AGED; PROTEINURIA;

EID: 33750594233     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001882     Document Type: Article

References (39)

1. US Renal Data System. USRDS 2004 Annual Data Report. Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2004.
2. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 1996; 125: 221-232.
3. Knowler WC, Pettitt DJ, Saad MF, Bennett PH. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev 1990; 6: 1-27.
4. Knowler WC, Bennett PH, Bottazzo GF, Doniach D. Islet cell antibodies and diabetes mellitus in Pima Indians. Diabetologia 1979; 17: 161-164.
5. Dabelea D, Palmer JP, Bennett PH et al. Absence of glutamic acid decarboxylase antibodies in Pima Indian children with diabetes mellitus. Diabetologia 1999; 42: 1265-1266.
6. Hanson RL, Ehm MG, Pettitt DJ et al. An autosomal genomic scan for loci linked to type 2 diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet 1998; 63: 1130-1138.
7. Baier LJ, Permana PA, Traurig M et al. Mutations in the genes for hepatocyte nuclear factor (HNF)-1alpha, -4alpha, -1beta, and -3beta; the dimerization cofactor of HNF-1; and insulin promoter factor 1 are not common causes of early-onset type 2 diabetes in Pima Indians. Diabetes Care 2000; 23: 302-304.
8. Looker HC, Krakoff J, Nelson RG et al. Trends in treatment for diabetes and blood pressure: 1989-2003. Diabetes 2005; 54: A611.
9. Nelson RG, Morgenstern H, Bennett PH. An epidemic of proteinuria in Pima Indians with type 2 diabetes mellitus. Kidney Int 1998; 54: 2081-2088.
10. Nelson RG, Morgenstern H, Bennett PH. Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians. Diabetes 1998; 47: 1489-1493.
11. Pettitt DJ, Saad MF, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 438-443.
12. Nelson RG, Pettitt DJ, de Courten MP et al. Parental hypertension and proteinuria in Pima Indians with NIDDM. Diabetologia 1996; 39: 433-438.
13. Nelson RG, Pettitt DJ, Baird HR et al. Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1993; 36: 998-1001.
14. Lewis EJ, Hunsicker LJ, Bain RP, Rohde RP. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
15. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
16. Brenner BM, Cooper ME, deZeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
17. Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
18. Kasiske BL, Kalil RSN, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabete. A meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
19. Strippoli GFM, Craig M, Deeks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin 2 receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828.
20. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin angiotensins system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033.
21. Sievers ML, Nelson RG, Bennett PH. Decrease in mortality from diabetic nephropathy in Pima Indians [letter]. Diabetes Care 1996; 19: 777.
22. Burrows NR, Narva AS, Geiss LS et al. End-stage renal disease due to diabetes among Southwestern American Indians, 1990-2001. Diabetes Care 2005; 28: 1041-1044.
23. Pavkov ME, Sievers ML, Knowler WC et al. An explanation for the increase in heart disease mortality rates in diabetic Pima Indians. Effect of renal replacement therapy. Diabetes Care 2004; 27: 1132-1136.
24. Pavkov ME, Bennett PH, Sievers ML et al. Predominant effect of kidney disease on mortality in Pima Indians with or without type 2 diabetes. Kidney Int 2005; 68: 1267-1274.
25. Burrows NR, Wang J, Geiss L et al. Incidence of end-stage renal disease among persons with diabetes-United States, 1990-2002. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2005; 54: 1097-1100.
26. Burrows NR, Wang J, Geiss L et al. Incidence of end-stage renal disease among persons with diabetes - United States, 1990-2002. JAMA 2005; 294: 2962-2963.
27. Sakarcan A, Tenney F, Wilson JT et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 2001; 41: 742-749.
28. Wells T, Frame V, Soffer B et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 2002; 42: 870-880.
29. Hilgers KF, Dotsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 2004; 19: 956-961.
30. Fagot-Campagna A, Pettitt DJ, Engelgau MM et al. Type 2 diabetes among North American children and adolescents: an epidemiological review and public health perspective. J Pediatr 2000; 136: 664-672.
31. ADA Consensus Statement. Type 2 diabetes in children and adolescents. Diabetes Care 2000; 23: 381-389.
32. Shevky M, Stafford M. A clinical method for the estimation of protein in urine and other body fluids. Arch Intern Med 1923; 32: 222-225.
33. Chasson AL, Grady HJ, Stanley MA. Determination of creatinine by means of automatic chemical analysis. Tech Bull Regist Med Technol 1960; 30: 207-212.
34. World Health Organization. Diabetes Mellitus. World Health Organization: Geneva, 1985 (Tech.Rep.Ser.no. 727).
35. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
36. Miettinen OS. Standardization of risk ratios. Am J Epidemiol 1972; 96: 383-388.
37. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 419-448.
38. Mantel N. Chi-square test with one degree of freedom: extension of the Mantel-Haenszel procedure. J Am Stat Assoc 1963; 59: 690-700.
39. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator. National Institutes of Health: Washington, 1979, NIH publication no. 79-1949, pp 11-17.